Liquid Biopsy Market - Global Drivers, Restraints, Opportunities, Trends, and Forecasts: 2017-2023

  • ID: 4456384
  • Report
  • Region: Global
  • 120 Pages
  • Infoholic Research LLP
1 of 5
The Global Liquid Biopsy Market is Estimated to Witness a CAGR of 24.1% During the Forecast Period 2017-2023.

FEATURED COMPANIES

  • Biocept, Inc.
  • CareDx, Inc
  • F.Hoffmann-La Roche Ltd
  • Guardant Health
  • Illumina, Inc.,
  • Inivata Limited
  • MORE

Overview: Liquid biopsy is a minimally or non-invasive technology that detects molecular biomarkers using liquid sample without the need for costly or invasive procedures. These tests have considerable potential for early detection of cancer, treatment and recurrence monitoring, detection of genetic abnormalities in fetus, and graft rejection in transplantation patients. According to the estimation of National Cancer Institute, in the US around 1.6 million new cases of cancer are diagnosed, and 595,690 people have died due to cancer in 2016. According to the Canadian Cancer Society, 202,400 new cases of cancer and nearly 78,000 deaths are estimated in 2016. While in Europe 1.3 million people were diagnosed in 2015. Further, according to the study of World Health Organization, approximately 14 million new cancer cases were diagnosed and is expected to grow by about 70% over the next 2 decades.

The liquid biopsy market is booming due to the rising prevalence of cancer globally, advanced maternal age leading to growing chromosomal aberrations, and the increasing preference of non-invasive liquid biopsy tests over invasive tissue biopsy. The lack of sensitivity and specificity of liquid biopsy tests, high cost of the test with fewer reimbursement facilities, and the lack of trained professionals are some of the factors hampering the market growth. The markets in emerging countries are expected to grow at a rapid pace during the forecast period due to the increasing disease prevalence, healthcare awareness, and healthcare spending.

Market Analysis:

The Global Liquid Biopsy Market is estimated to witness a CAGR of 24.1% during the forecast period 2017-2023. The market is analyzed based on three segments, namely biomarker type, sample type, application, end-users, and regions.

Regional Analysis:

The regions covered in the report are North America, Europe, Asia Pacific, and Rest of the World (RoW). The Americas is set to be the leading region for the liquid biopsy market growth followed by Europe. Asia Pacific and RoW are set to be the emerging regions.

Biomarker Type Analysis:

The global liquid biopsy market by biomarker type is segmented into circulating tumor cell (CTC), cell-free DNA (cfDNA), extracellular vesicles, and others. Cell-free DNA (cfDNA) segment is the largest segment in 2016 due to its wide range of application in prenatal testing, transplantation diagnostics, and oncology. 

Sample Type Analysis:

The global liquid biopsy market by sample type is segmented into blood and others. Blood sample occupies the major market share in 2016 since most of the tests currently available in the market are blood-based tests.

Application Analysis:

The global liquid biopsy market by application is segmented into cancer and non-cancer applications. Cancer segment occupies the largest market share and is expected to be the fastest growing segment during the forecasted period. Cancer application is further segmented by cancer indication and clinical application.

End-users Analysis:

The global liquid biopsy market by end-users is segmented into hospital and reference laboratories, academic and research institutes, and others. Hospital and reference laboratories occupied a major share of liquid biopsy market in 2016 due to the increasing volume of test samples outsourced to this segment.

Key Players:

Biocept, Inc, F- Hoffmann-la Roche, Illumina, Inc, Natera Inc, Trovagene Inc., Qiagen N.V., Laboratory Corporation of America Holdings, Beijing Genomics Institute, Guardant Health, Inc., Genomic Health, MDx Health SA, Guardant Health, Inc., Myriad Genetics, Inc., and other predominate & niche players.

Competitive Analysis:

Currently, cancer tests dominate the global liquid biopsy market. A lot of new players are concentrating on this market to provide ground-breaking test with high sensitivity, specificity, and less turnaround time. Major market players are acquiring small companies to enhance their product portfolio and strengthen their leadership position in the market. Apart from this, the major players are launching innovative tests to have an upper hand in the market. For instance, in September 2017, Biocept launched Liquid Biopsy test for NRAS mutations.

Benefits:

The report provides complete details about the usage and adoption rate of liquid biopsy tests in various applications and regions. With that, key stakeholders can know about the major trends, drivers, investments, vertical player’s initiatives, government initiatives toward the test adoption in the upcoming years along with the details of commercial tests available in the market. Moreover, the report provides details about the major challenges that are going to impact the market growth. Additionally, the report gives complete details about the key business opportunities to key stakeholders to expand their business and capture the revenue in specific verticals to analyze before investing or expanding their business in this market.

READ MORE
Note: Product cover images may vary from those shown
2 of 5

FEATURED COMPANIES

  • Biocept, Inc.
  • CareDx, Inc
  • F.Hoffmann-La Roche Ltd
  • Guardant Health
  • Illumina, Inc.,
  • Inivata Limited
  • MORE

1 Industry Outlook
1.1 Industry overview
1.2 Total addressable market
1.3 Industry Trends

2 Report Outline
2.1 Report Scope
2.2 Report Summary
2.3 Research Methodology
2.4 Report Assumptions

3 Market Snapshot
3.1 Market Definition 
3.2 Importance of Cell-Free DNA testing
3.3 Complications of Cell-Free DNA testing
3.4 Segmented Addressable Market (SAM)
3.5 Industry Trends
3.6 Related Markets
3.6.1 Liquid biopsy market
3.6.2 Transplantation Diagnostics Market

4 Market Outlook
4.1 Overview
4.2 Regulatory framework
4.3 Funding scenario
4.4 Market segmentation
4.5 PEST Analysis
4.6 Porter 5(Five) Forces

5 Market Characteristics
5.1 DRO - Global Cell-free DNA testing Market Dynamics
5.1.1 Drivers
5.1.1.1 Rising incidence of babies with chromosomal disorders due to increasing number of late pregnancies
5.1.1.2 Rising number of cancers
5.1.1.3 Growing demand through non-invasive procedures for early disease diagnosis
5.1.2 Opportunities
5.1.2.1 Increase healthcare spending and growing healthcare awareness in emerging countries
5.1.2.2 Increase in mergers & acquisitions
5.1.3 Restraints
5.1.3.1 High test cost with less reimbursement facilities
5.1.3.2 Ethical issues
5.1.3.3 Lack of skilled professionals for performing advanced diagnostic testing

6 Test Types: Market Size and Analysis
6.1 Overview
6.2 Non-invasive prenatal tests (NIPT)
6.3 Circulating tumour DNA tests
6.4 Donor-derived cell free DNA tests

7 Application: Market Size and Analysis
7.1 Overview
7.2 Prenatal testing
7.3 Cancer
7.4 Transplantation diagnostics

8 Regions: Market Size and Analysis
8.1 Overview
8.2 North America
8.2.1 Overview
8.2.2 United states
8.2.3 Canada
8.3 Europe
8.3.1 Overview
8.3.2 United Kingdom
8.3.3 Germany
8.3.4 France
8.3.5 Spain
8.4 APAC
8.4.1 Overview
8.4.2 India
8.4.3 China
8.5 Rest of the World
8.5.1 Overview
8.5.2 Brazil
8.5.3 Middle East

9 Competitive Landscape
9.1 Overview

10 Vendor Profiles
10.1 Natera, Inc.
10.1.1 Overview
10.1.2 Natera Inc.: Product offerings
10.1.3 NATERA, INC.: Recent Developments
10.1.4 Geographic Presence
10.1.5 Business Focus
10.1.6 SWOT Analysis
10.1.7 Business Strategy
10.2 Laboratory Corporation of America Holdings (LABCORP)
10.2.1 Overview
10.2.2 Laboratory Corporaton Of America Holdings: Product Offerings
10.2.3 Laboratory Corporation Of America Holdings: Recent Developments
10.2.4 Business Unit
10.2.5 Geographic Presence
10.2.6 Business Focus
10.2.7 SWOT Analysis
10.2.8 Business Strategy
10.3 Illumina, Inc.,
10.3.1 Overview
10.3.2 Illumina, INC: Product offerings
10.3.3 Illumina, INC: Recent Developments
10.3.4 Geographic Presence
10.3.5 Business Focus
10.3.6 SWOT Analysis
10.3.7 Business Strategy
10.4 BEIJING GENOMICS INSTITUTE
10.4.1 Overview
10.4.2 Beijing Genomics Institute: Product offerings
10.4.3 Beijing Genomics Institute: Recent Developments
10.4.4 Business Focus
10.4.5 SWOT Analysis
10.4.6 Business Strategy
10.5 F.Hoffmann-La Roche Ltd
10.5.1 Overview
10.5.2 F. Hoffmann-la Roche: Product Offerings
10.5.3 F. Hoffmann-la roche.: Recent Developments
10.5.4 Business Unit
10.5.5 Geographic Presence
10.5.6 Business Focus
10.5.7 SWOT Analysis
10.5.8 Business Strategy
Companies to Watch For
10.6 CareDx, Inc
10.6.1 Overview
10.6.2 caredx: Recent Developments
10.7 LifeCodexx AG
10.7.1 Overview
10.7.2 LifeCodexx AG: Recent Developments
10.8 Biocept, Inc.
10.8.1 Overview
10.8.2 Biocept, Inc.: Recent Developments
10.9 Quest Diagnostics
10.9.1 Overview
10.9.2 Quest Diagnostics: Recent Developments
10.10 Guardant Health
10.10.1  Overview
10.10.2  Guardant Health: Recent Developments
10.11 Inivata Limited
10.11.1  Overview
10.11.2 Inivata Limited: Recent Developments
10.12 Personal Genome Diagnostics
10.12.1  Overview
10.12.2  Personal Genome Diagnostics: Recent Developments
10.13 Trovagene
10.13.1 Overview
10.13.2  Trovagene, Inc.: Recent Developments

Annexure
Abbreviations

Note: Product cover images may vary from those shown
3 of 5

Loading
LOADING...

4 of 5
  • Beijing Genomics Institute
  • Biocept, Inc.
  • CareDx, Inc
  • F.Hoffmann-La Roche Ltd
  • Guardant Health
  • Illumina, Inc.,
  • Inivata Limited
  • Laboratory Corporation of America Holdings (LABCORP)
  • LifeCodexx AG
  • Natera, Inc.
  • Personal Genome Diagnostics
  • Quest Diagnostics
  • Trovagene
Note: Product cover images may vary from those shown
5 of 5
Note: Product cover images may vary from those shown
Adroll
adroll